Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Reuters11-07

Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581501208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581501208","market":"nz","top_or_hot":-1,"title":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbfQFvL:1","article_id":"2581501208","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581501208","pubTimestamp":1762462971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $ million, while Adjusted EBITDA was $ million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $ million, compared to $ million last year, with Adjusted EBITDA at $ million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc.","BK4121":"生命科学工具和服务"},"translate_title":"Maravai LifeSciences报告第三季度收入为4160万美元，净亏损为4510万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":0.9},"content_text":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    \n\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581501208","isCrawlerRequest":true}